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Abstract: Investigations for NHL treatment are oriented towards radiolabelled therapeutics. This research
focuses on formulation and characterization of a new, ready to label immunoconjugate, 1B4M-DTPA-rituximab,
which is suitable for labeling with Lu-177. The conjugation was performed using 20-fold molar excess of the
bifunctional chelating agent, 1B4M-DTPA and subsequent lyophilization. The characterization of the
(radio)immunoconjugate was performed using SE-HPLC, SDS-PAGE and MALDI-TOF-MS. The results show
that the conjugation reaction yields immunoconjugates with average of 8.3 chelating groups per one rituximab
molecule and the subsequent lyophilization did not affect the integrity, the structure, or radionuclide-binding
properties. The radiolabelling with 555 GBq/mg Lu-177 resulted in over 95% radiochemical purity, which makes
this agent a good candidate for further investigation of biological and pharmacological potency in NHL therapy.
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INTRODUCTION degradation processes. These processes include
Non-Hodgkin’s lymphoma (NHL) is a form of blood isomerization, oxidation or disulfide bond rearrangements
cancer with origin in lymphatic system. [16-19]. The presence of water either as a reactant or a
More than 90% of B-cell lymphoma cells express solvent, is critical for many routes of chemical degradation
CD20 receptor who has proven to be an excellent target that lead to protein instability. Therefore, lowering the
for the treatment of B-cell lymphoma [1]. Investigations water content may provide resistance to chemical
for NHL therapy are mainly focused to development of modification. A common approach of stabilization of
antibody against CD20 antigens [2]. As a result, rituximab therapeutic proteins is lyophilization in which retention of
(chimeric antibody), was included in therapy [3, 4]. A step native protein structure in the dried solid and prevention
further in NHL therapy was the implementation of of degradation during storage is achieved [20, 21].
radiolabelled anti-CD20    monoclonal    antibodies, Y- The  purpose  of  this  investigation  was to 90
ibritumomab (Zevalin) and I-tositumomab (Bexxar) [5-8]. establish a technology for a  “ready-to-use”  lyophilized131
Other rituximab radioimmunoconjugates are under kit formulation of conjugated rituximab suitable for
investigation for use in NHL therapy. There are on-going labeling with Lu-177, which meets the quality control
studies investigating various radionuclides for rituximab criteria. As bifunctional chelating  agent,  a  derivate of
labeling, such as Y [9], In [10, 11], Sm [12] and Lu DTPA, 1B4M-DTPA  (2-(4-isothiocyanatobenzyl)-6-90 111 153 177
[9, 13, 14]. The radionuclides can be attached to the methyl- diethylene-triaminepentaacetic acid) was used.
antibody through different chelating agents and various Various protein characterization methods were used to
derivatives of the acyclic agent diethylene triamine determine the possible changes in physicochemical
pentaacetic acid (DTPA) and the macrocyclic agent properties of rituximab   conjugate,   including   size-
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid exclusion HPLC (SE-HPLC), SDS-PAGE and MALDI-TOF-
(DOTA) are also under investigation [15]. MS. The main goal of this investigation was
Owing to its immunoglobulin protein nature, characterization of the obtained immunocomplex and
rituximab posseses very complex molecular  structure  and analysis of its physicochemical and radionuclide binding
may go through a variety of chemical and physical properties.
adsorption to surfaces, unfolding, aggregation,
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MATERIALS AND METHODS applied per lane in 12% bisacrylamide gel under reducing
Conjugation of Rituximab: 1B4M-DTPA was dissolved in R-250, Sigma) was performed according to the
0.1 M PBS (pH 8.0) to final concentration of 10 mg/mL. manufacturer’s instructions. All chemicals used were
Calculated amounts of 1B4M-DTPA required to give a 20- reagent and HPLC grade. As a molecular marker, Low
fold molar excess over the amount of rituximab were added molecular weight marker (Amersham GE Healthcare) was
to the purified rituximab in 0.1 M PBS (pH 8.0). The mixture used. For reproducibility, the electrophoresis was
was incubated overnight (4°C with gentle shaking). repeated in triplicates. 
Purification of the conjugates was made with ultrafiltration
(Ultracel - 30K, Millipore, Ireland), by washing the Protein  Characterisation   by   MALDI-TOF   MS:®
immunoconjugates with 0.05 M ammonium acetate, pH 7.0.
Freeze Drying Procedure: The freeze dried process was
performed using Labconco Free Zone Stoppering Tray
Dryer, (USA) using a protocol described by Park et al., in
2013 [22], modified to our experience. Briefly, the liquid
immunoconjugates were filled in 10 mL type I glass tubing
vials using a fill volume of 1 mL and were partially
stoppered with corresponding lyophilization stoppers.
Then, the vials were were equally distributed on the
shelves of the freeze-dryer, including empty vials with
thermocouples on each shelf to monitor the temperature
variation during the process. The samples were loaded at
shelf temperature of 5°C and the temperature was
decreased to -40°C at 0.40°C/min and held for 3 h. In order
to achieve complete crystallization and to obtain the
desired cake structure, an annealing step was included, at
-15 °C, The freezing step was completed in 10 h. The
primary drying was performed at temperature of -10°C for
25 h and the secondary drying at shelf temperature 25°C
for 11 h. Upon finishing the process, the vials were
stoppered and kept at 4°C until analysis. 
Determination of the Immunoconjugate Concentration:
The concentration of the antibody/immunoconjugate was
determined with UV spectrophotometer (Jenway UV/VIS
spectrophotometer 6715) at 280 nm, in triplicate, using the
standard extinction coefficient for antibodies, 1.4
mL/mg/cm. The concentration of the lyophilized
preparations was measured after complete reconstitution
in 1 mL 0.9% NaCl.
Protein Integrity Test Using Sodium Dodecyl Sulphate-
polyacrylamide Gel Electrophoresis (SDS-PAGE):
Sodium dodecyl  dulphate-polyacrylamide  gel
electrophoresis was performed on the mini-gel system (GE
Healthcare/Amersham Biosciences) according to Laemmli
protocol [23]. About 5 µL of sample was mixed with 10 µL
of sample buffer. The samples were boiled for 5 min at
95°C and approximately 5 µL of each preparation was
conditions. Coomassie staining (Coomassie Brilliant Blue
Matrix-Assisted Laser Desorption Ionization time-of-flight
(MALDI-TOF) mass spectrometry was performed with
Voyager-De MALDI-TOF (Applied Biosystems).
Both characterization of the conjugates and
determination of the average number of chelator groups
attached to each antibody molecule was performed by
MALDI-TOF. A volume of 10 µL conjugated rituximab
solution  was   diluted  (1:10)  with  a  matrix  solution of
3,5-dimethoxy-4-hydroxycinnamic acid (10 mg/mL) to a
final concentration of about 10 pmol/ìL. 1-2 ìL of the final
solution was applied to the sample target prior insertion
into the high vacuum chamber of the mass spectrometer.
The results  were  recorded in aquisition mass range of
140-170 kDa.
Radiolabeling  of the Freeze Dried Immunoconjugate
with Lutetium-177: The radiolabeling of the freeze-dried
immunoconjugate was performed after reconstitution in
0.9% NaCl, in the presence of acetate ions at pH 7.0 with
Lutetium-177 with specific activity of 555 GBq/mg, at room
temperature. The excess of Lutetium-177 was scavenged
with DTPA (0.01M, pH 6.0). The radiolabeled
immunoconjugates were obtained with high radiochemical
yield. The radiochemical purity was determined using
HPLC.
Size-exclusion   HPLC:  Obtained  radioimmunoconjugate
was   characterized   with   SE-HPLC.   Apparatus
conditions  were:  column  Zorbax  Bio  Series  GF-250;
sample volume: 20 ìl; mobile phase: 0.9% NaCl flow rate:
1 mL/min; UV detection at 280 nm and radiometric
detection.
RESULTS AND DISCUSSION
To assess the stability of rituximab conjugate,
several different analytical methods were performed and
protein characterization methods were used to determine
possible changes of rituximab conjugate before and after
lyophilization.
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Fig. 1: Scheme of the applied lyophilization protocol. 1B4M-DTPA-rituximab conjugates (Before and after
Fig. 2: Reducing SDS-PAGE lane patterns for 1B4M- reducing SDS-PAGE results, compared to the
DTPA-rituximab conjugate before lyophilization commercially available rituximab sample, showed no clear
(1), 1B4M-DTPA-rituximab conjugate, after indication for antibody degradation. At the same time, no
lyophilization (2); rituximab (3) (1 mg/mL), M is a other degradation entities were detected using this
low molecular weight marker; technique. Almost identical results were obtained after
During lyophilization, the freezing step is considered immunoconjugate products stored at 4°C (Results not
as important as the drying step, because of possible shown).
effects on the integrity of the protein. It is known that It is known that the active ester groups of the
faster freezing creates ice crystals smaller, while slower bifunctional chelating agent react with the neutral form of
freezing creates larger crystals, which in turn affects the the antibody amine groups, forming thiourea-type bonds
primary drying process. However, it has been shown that with the å-amino residues of lysine [14]. The structure of
rapid freezing may lead to formation of multiple the used chelating agent for conjugation of rituximab is
aggregates in bovine and human IgG, other than slow shown in Figure 3.
freezing, because it leads to a higher percentage of protein
denaturation [24, 25]. 
Instability of the protein containing pharmaceutical
formulation is a common problem because of the
aggregate formation. Aggregates can be present in liquid
or solid form, from which they can be easily dissolved or
they can stay in not dissolved form [26]. Many strategies
are available for improve formulation development of
anticancer drugs [27]. Our previous research showed that
the protocol employed (Fig. 1) showed minimal or no
changes in the immunoconjugate upon lyophilization,
using a formulation without added cryoprotectants.
Therefore, this lyophilization protocol was employed in Fig. 3: Structure of used 1B4M-DTPA for rituximab
the preparation of the kit formulation. conjugation
In order to assess the integrity of the protein and
purity after conjugation and lyophilization, gel
electrophoresis was performed on SDS-PAGE gels using
12% bisacrylamide gel. The loaded samples were rituximab
(Commercial sample diluted to 1 mg/mL), conjugated liquid
rituximab-1B4M-DTPA and reconstituted lyophilizate,
both in concentration of 1 mg/mL. Figure 2 shows the
SDS-PAGE patterns for rituximab-1B4M-DTPA
conjugates, compared to unconjugated rituximab as
control sample.
lyophilization) were resolved in two distinct Mw species
that migrated in two bands (upper band at ~50 kDa and
lower band at ~25 kDa), a migration behavior typical for
IgG antibodies composed of two identical subunits, each
composed by two polypeptide chains: two heavy and two
light chains, linked via disulfide bonds. The obtained
fragments correspond to molecular masses of rituximab
heavy and light chain given at the corresponding
literature [28]. 
As it is shown in Figure 2, the reducing SDS-PAGE
patterns for rituximab and 1B4M-DTPA -rituximab
immunoconjugates were with very similar intensity. The
one month integrity test on 1B4M-DTPA-rituximab
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Fig. 4: MALDI-TOF results for 1B4M-DTPA-rituximab conjugate.
Fig. 5: SE-HPLC of Lu-1B4M-DTPA -rituximab177
In order to obtain good radiolabeling yield, it is 146848 Da (Unconjugated mAb) and 151506 Da
important that enough chelator molecules are conjugated (Conjugated mAb), which corresponds to an average of
to  the  antibody.  This is achieved by using a molar 8.3 groups of 1B4M-DTPA per molecule of rituximab. No
excess of the chelator during the conjugation reaction. structural changes in terms of appearance of additional
Therefore, one of the most important properties of the peaks were observed. 
immunoconjugates is the average number of conjugated There are studies where 4.25 ± 1.04 DOTA-SCN
chelator molecules. Determination of the average number molecules were attached to each antibody molecule [9]
of 1B4M-DTPA molecule attached to each antibody and five  DOTA  molecules  were  conjugated to
molecule was performed by MALDI-TOF MS. This is a MORAb-003, with no apparent loss of immunoreactivity
rapid and sensitive technique for characterization of [31]. These results are found to be sufficient for prompt
peptides and proteins and it is used successfully in subsequent labelling with radioisotope. Our results of
biochemical and biotechnological areas for analysis of average of 8.3 groups of 1B4M-DTPA per molecule of
therapeutic proteins, peptides, glycoproteins, complex rituximab, pointed that this number can be increased using
carbohydrates and oligonucleotides. Many studies different experimental conditions, as molar ratios for
comparing mass spectra of intact antibodies conjugated conjugation, for example. Highly substituted anti-tumor
with chelating agents (DTPA, macrocycle 12N4) or with antibody leads to formation of immunoconjugates with
drugs (Calicheamicin, methotrexate, mitoxantrone) with the high specific activity which is a valuable option for
corresponding unconjugated antibodies, exist [29, 30]. radioimmunotherapy [9].
MALDI-TOF results for 1B4M-DTPA -rituximab Radiolabeling of the immunoconjugate was
conjugate, after lyophilization (Shown on Figure 4), show performed after reconstitution of the lyophilized
presence of two major peaks corresponding to a Mw of preparation with 0.9 % saline. Representative SE-HPLC
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profile of the radiolabeled immunoconjugate is shown in 5. Macklis, R.M and B. Pohlman, 2006.
Figure 5. In the chromatogram obtained, a presence of
only one peak is registered, that corresponds to the
radiolabeled antibody. The radiochemical purity of the
immunoconjugate is over 95%, which meets quality
criteria.
This study was conducted to evaluate the
physicochemical properties of the obtained lyophilized
formulation of rituximab-1B4M-DTPA conjugate. Based
on the results, we can conclude that conjugation and
lyophilization process did not affect structure properties
and caused no post-lyophilization modifications, giving
a good base for inclusion of this kit formulation in further
investigations.
CONCLUSION
The results of this study concluded that the
conjugation reaction in 20-fold molar excess of
bifunctional chelating agent, yields immunoconjugates
that were lyophilized in a manner that did not affect its
integrity, the structure or radionuclide-binding properties.
Furthermore, radiolabeling of this lyophilized (kit)
formulation of 1B4M-DTPA-rituximab conjugate, having
approximate 8 molecules of chelator per antibody molecule
with Lu results in radioimmunoconjugates with good177
radiochemical yield and high radiochemical purity, with no
visible aggregation. Still, further experiments are needed
in order to develop a promising radiopharmaceutical for
the treatment of non-Hodgkin’s lymphoma. 
REFERENCES
1. Dillman, R.O., 2001. Monoclonal antibody therapy for
lymphoma. Cancer Practice, 9: 71-80.
2. Dillman, R.O., 2006. Radioimmunotherapy of B-cell
lymphoma with radiolabeled anti-CD20 monoclonal
antibodies.   Clinical   and   Experimental  Medicine,
6: 1-12.
3. McLaughlin, P., A.J. Grillo-López, B.K. Link, R. Levy,
M.S.   Czuczman,   M.E.   Williams,   M.R.  Heyman,
I. Bence-Bruckler, C.A. White, F. Cabanillas, V. Jain,
A.D. Ho, J. Lister, K. Wey, D. Shen and B.K. Dallaire,
1998. Rituximab chimeric anti-CD20 monoclonal
antibody therapy for relapsed indolent lymphoma:
half of patients respond to a four-dose treatment
program. Journal of Clinical Oncology, 16: 2825-2833.
4. Sathiya, M and K. Muthuchelian, 2009. Significance
of Immunologic Markers in the Diagnosis of
Lymphoma. Academic Journal of Cancer Research
2(1): 40-50.
Radioimmunotherapy for non-Hodgkin’s lymphoma:
a review for radiation oncologists. International
Journal  of  Radiation  Oncology, Biology, Physics,
66: 833-841.
6. Wiseman, G.A, C.A White, T.E Witzig, L.I. Gordon,
C. Emmanouilides, A. Raubitschek, N. Janakiraman,
J. Gutheil, R.J. Schilder, S. Spies, D.H.S. Silverman
and A.J. Grillo-Lopez, 1999. Radioimmunotherapy of
relapsed non-Hodgkin's lymphoma with Zevalin,
a Y-labeled anti-CD20 monoclonal antibody. Clinical90
Cancer Research, 5: 3281-3286.
7. Kaminski, M.S., J. Estes, K.R. Zasadny, I.R. Francis,
C.W. Ross, M. Tuck, D. Regan, S. Fisher, J. Gutierrez,
S. Kroll, R. Stagg, G. Tidmarsh and R.L. Wahl, 2000.
Radioimmunotherapy with iodine I tositumomab131
for relapsed or refractory B-cell non-Hodgkin
lymphoma: updated results and long term follow-up
of the University of Michigan experience. Blood,
96(4): 1259-1266.
8. Dillman, R.O., 2002. Radiolabeled anti-CD20
monoclonal antibodies for the treatment of B-cell
lymphoma.   Journal     of      Clinical      Oncology,
20: 3545-3557.
9. Mohsin, H., J. Fitzsimmons, T. Shelton, T.J. Hoffman,
C.S. Cutler,  M.R.  Lewis,  P.S.  Athey,  G.  Gulyas,
G.E. Kiefer, R.K. Frank,  J.  Simon,  S.Z.  Lever  and
S.S. Jurisson, 2007. Preparation and biological
evaluation of In, Lu and Y labeled DOTA111 177 90
analogues conjugated to B72.3. Nuclear Medicine
and Biology, 34: 493-502.
10. Gholipour, N., A.R. Jalilian, A. Khalaj, F. Johari-Daha,
K.   Yavari,    O.    Sabzevari,    A.R.    Khanchi   and
M.  Akhlaghi,  2014.  Preparation  and  radiolabeling
of  a  lyophilized  (kit)  formulation  of  DOTA-
rituximab with Y and In for domestic90 111
radioimmunotherapy   and   radioscintigraphy of
Non-Hodgkin’s Lymphoma. DARU Journal of
Pharmaceutical Sciences, 22: 58.
11. Jalilian,  A.R,  D. Sardari,  L.  Kia,  P.  Rowshanfarzad,
J.  Garousi,  M.  Akhlaghi,  S.  Shanehsazzadeh  and
M. Mirzaii, 2008. Preparation, quality control and
biodistribution studies of two [ In]-Rituximab111
immunoconjugates.    Scientia     Pharmaceutica,
76(2): 151-170.
12. Bahrami-Samani,   A.,   M.   Ghannadi-Maragheh,
A.R.   Jalilian,    H.    Yousefnia,    J.    Garousi    and
S. Moradkhani, 2009. Development of Sm-DTPA-153
rituximab   for   radioimmunotherapy.   Nukleonika,
54: 271-277.
World J. Med. Sci., 11 (4): 535-540, 2014
540
13. Thakral,  P.,   S.   Singla,   M.P.  Yadav,  A.  Vasisht, 23. Laemmli, U.K., 1970.Cleavage of structural proteins
A. Sharma, S.K. Gupta, C.S. Bal and A. Malhotra, during the assembly of the head of bacteriophage.
2014. An approach for conjugation of Lu-DOTA- Nature, 227: 680-685.177
SCN-Rituximab (BioSim) and its evaluation for 24. Sarciaux,  J.M.,  S.  Mansour,  M.J.  Hageman  and
radioimmunotherapy of relapsed and refractory B-cell S.L. Nail, 1999. Effects of buffer composition and
non Hodgkins lymphoma patients. Indian Journal of processing conditions on aggregation of bovine IgG
Medical Research, 139: 544-554. during freeze-drying. Journal of Pharmaceutical
14. Forrer,  F.,  J.  Chen,  M.  Fani,  P.  Powell,  A.  Lohri, Science, 88(12): 1354-1361.
J. Müller-Brand, G. Moldenhauer and H.R. Maecke, 25. Lang, R., G. Winter, L. Vogt, A. Zürcher, B. Dorigo
2009. In vitro characterization of (177)Lu-radiolabeled and B. Schimmele, 2009. Rational Design of a Stable,
chimeric anti-CD20 monoclonal antibody and a Freeze-Dried Virus-Like Particle-Based Vaccine
preliminary dosimetry study. European Journal of Formulation. Drug Development and Industrial
Nuclear     Medicine    and     Molecular     Imaging, Pharmacy, 35: 83-97. 
36: 1443-1452. 26. Rathore, N. and R.S. Rajan, 2008. Current
15. Liu, S., 2008. Bifunctional coupling agents for perspectives on stability of protein drug products
radiolabeling of biomolecules and target-specific during formulation, fill and finish operations.
delivery of metallic radionuclides. Advanced Drug Biotechnology Progress, 24(3): 504-14.
Delivery Reviews, 60(12): 1347-1370. 27. Yadav, S.K., N. Parvez and P.K. Sharma, 2014. An
16. Cleland, J.L, M.F. Powell and S.J. Shire, 1993. overview and new strategies to improve formulation
Development of stabile protein formulations: A close development of anticancer drugs. Advances in
look at protein aggregation, deamidation and Biological Research, 8(6): 233-243.
oxidation. Critical Reviews in Therapeutic Drug 28. Maleki,      L.A.,       J .      Majidi,      B.      Baradaran,
Carrier Systems, 10: 307-377. J.  Abdolalizadeh,  T.   Kazemi,   A.A.   Maleki   and
17. Manning, M.C., D.K. Chou, B.M. Murphy, R.W. K.S. Sepehr, 2013. Large scale generation and
Payne and D.S. Katayama, 2010. Stability of protein characterization of anti-human CD34 monoclonal
pharmaceuticals: an update. Pharmaceutical antibody in ascetic fluid of Balb/c mice. Advanced
Research, 27: 544-575. Pharmaceutical Bulletin, 3(1): 211-216.
18. Wang, W., S. Singh, D.L. Zeng, K. King and S. Nema, 29. Siegel, M.M., I.J. Hollander, P.R. Hamann, J.P. James,
2007. Antibody structure, instability and formulation. L. Hinman, B.J. Smith, A.P.H. Farnsworth, A. Phipps
Journal of Pharmaceutical Sciences, 96: 1-26. and D.J. King, 1991. Matrix-assisted UV-laser
 19. Wang, W., 2005. Protein aggregation and its desorption/ionization mass spectrometric analysis of
inhibition in biopharmaceutics. International Journal monoclonal  antibodies  for  the  determination of
of Pharmaceutics, 289: 1-30. carbohydrate, conjugated chelator and conjugated
20. Breen, E.D, J.G. Curley, D.E. Overcashier, C.C. Hsu drug content. Analitycal Chemistry, 63(21): 2470-81.
and S.J. Shire, 2001. Effects of moisture on the 30. Wakankar, A., Y. Chen, Y. Gokarn and F.S. Jacobson,
stability of a lyophilized humanized monoclonal 2011. Analytical methods for physicochemical
antibody. Pharmaceutical Research, 18: 1345-1353. characterization of antibody drug conjugates. mAbs,
21. Andya, J.D., C.H. Chung and S.J. Shire, 2003. 3(2): 161-172.
Mechanisms of Aggregate Formation and 31. Smith-Jones     P.M.,     N.P.     Taskar,      W.     Cao,
Carbohydrate Excipient Stabilization of Lyophilized J. O'Donoghue, M.D. Philips, J. Carrasquillo, J.
Humanized Monoclonal Antibody Formulations. Konner, L.J. Old and S.M. Larson, 2008. Preclinical
AAPS Pharm Sci, 5(2): Article 10. radioimmunotargeting of folate receptor alpha using
22. Park, J., K. Nagapudi, C. Vergara, R. Ramachander, the monoclonal antibody conjugate DOTA-MORAb-
J.S. Laurence and S. Krishnan, 2013. Effect of pH and 003. Nuclear Medicine and Biology, 35(3): 343-351.
excipients on structure, dynamics and long-term
stability of a model IgG1 monoclonal antibody upon
freeze-drying. Pharmaceutical Research, 30: 968-984.
